Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Invir.IO

PoxSTG, a novel chimeric poxvirus with improved oncolytic potency

P Erbs et al.AACR 2023Download the poster herePoster Presentation

Published 19 April 2023
Categorized as -others, 2023, Invir.IO, Publication

Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 17 April 2023
Categorized as -others, 2023, Invir.IO, Publication

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as 2023, Invir.IO, Publication, TG6050-en

Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration

Transgene recieves approval to start a Phase I trial of TG6050 15

Published 6 January 2023
Categorized as 2023, categorie-orpheline, dates, Invir.IO, Press release, TG6050-en

Transgene announces Financial Calendar for 2023

Transgene announces Financial Calendar for 2023 15

Published 4 January 2023
Categorized as 2023, dates, Invir.IO, Press release, TG6002

R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

TRANSGENE R&D DAY

Published 27 September 2022
Categorized as 2022, Invir.IO, Press release, TG4001, TG4001, TG4050, TG6002

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Published 12 September 2022
Categorized as 2022, Invir.IO, Press release, TG6002

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Transgene and bioinvent announce clinical collaboration

Published 28 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene and BioInvent announce positive progress for BT-001

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 27 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors

Published 18 January 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Posts pagination

Newer posts Page 1 Page 2 … Page 6 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu